Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?

Comment

Michael L Friedlander et al. J Clin Oncol. 2013.

. 2013 Jun 20;31(18):2362.

doi: 10.1200/JCO.2012.47.7927. Epub 2013 May 13.

No abstract available

Comment in

Reply to M.L. Friedlander et al.
Spriggs DR. Spriggs DR. J Clin Oncol. 2013 Jun 20;31(18):2363. doi: 10.1200/JCO.2012.48.3743. J Clin Oncol. 2013. PMID: 23930276 No abstract available.
Reply to M.L. Friedlander et al.
Colombo N. Colombo N. J Clin Oncol. 2013 Jun 20;31(18):2363. doi: 10.1200/JCO.2012.48.3750. J Clin Oncol. 2013. PMID: 23930277 No abstract available.

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P. Colombo N, et al. J Clin Oncol. 2012 Nov 1;30(31):3841-7. doi: 10.1200/JCO.2011.38.8082. Epub 2012 Sep 17. J Clin Oncol. 2012. PMID: 22987083 Clinical Trial.
Drug development for chronic cancers: time to think differently?
Spriggs DR. Spriggs DR. J Clin Oncol. 2012 Nov 1;30(31):3779-80. doi: 10.1200/JCO.2012.42.3269. Epub 2012 Sep 17. J Clin Oncol. 2012. PMID: 22987092 No abstract available.